

## LIST OF TABLES

Sr. No.	Title	Page no.
<b>CHAPTER I</b>		
Table 1.1	Genetic susceptibility loci identified in Gujarat population.	12
Table 1.2	Interplay of cytokines and oxidative stress in vitiligo.	23
<b>CHAPTER II</b>		
Table 2.1	Demographic characteristics of patients with vitiligo and controls.	47
Table 2.2	Details of primers and restriction enzymes used for genotyping of single nucleotide polymorphisms.	49
Table 2.3	Details of primers used for gene expression analysis.	51
Table 2.4	Distribution of genotype and allele frequencies of <i>PSMB8</i> rs2071464 and <i>TAPI</i> rs1135216 polymorphisms in vitiligo patients and controls.	56
Table 2.5	Distribution of genotype and allele frequencies of <i>PSMB8</i> rs2071464 and <i>TAPI</i> rs1135216 polymorphisms in different subsets of vitiligo patients and controls.	57
Table 2.6	Distribution of haplotypes frequencies of <i>PSMB8</i> rs2071464 and <i>TAPI</i> rs1135216 polymorphisms in vitiligo patients and controls.	58
Table 2.7	<i>In silico</i> prediction results for <i>PSMB8</i> rs2071464 polymorphism.	62
Table 2.8	<i>In silico</i> prediction results for <i>TAPI</i> rs1135216 polymorphism.	63
Table 2.9	Distribution of genotype and allele frequencies of <i>MTHFR</i> rs1801133 and rs1801131 polymorphisms in vitiligo patients and controls.	65
Table 2.10	Distribution of genotype and allele frequencies of <i>MTHFR</i> rs1801133 and rs1801131 polymorphisms in different subsets of vitiligo patients and controls.	66
Table 2.11	Distribution of haplotypes frequencies of <i>MTHFR</i> rs1801133 and rs1801131 polymorphisms in vitiligo patients and controls.	67
Table 2.12	<i>In silico</i> prediction results for <i>MTHFR</i> rs1801133 and rs1801131 polymorphisms.	67
Table 2.13	Distribution of genotype and allele frequencies of <i>XBPI</i> -116 G/C rs2269577 polymorphism in vitiligo patients and controls.	70
Table 2.14	Distributions of genotype and allele frequencies of <i>XBPI</i> -116 G/C rs2269577 polymorphisms in different subsets	70

	of vitiligo patients and controls.	
Table 2.15	Distribution of genotype and allele frequencies of <i>IL17A</i> rs2275913 and rs8193036 polymorphisms in vitiligo patients and controls.	76
Table 2.16	Distributions of genotype and allele frequencies of <i>IL17A</i> rs2275913 and rs8193036 polymorphisms in different subsets of vitiligo patients and controls.	77
Table 2.17	Distribution of haplotype frequencies of <i>IL17A</i> rs2275913 and rs8193036 polymorphisms in vitiligo patients and controls.	78
Table 2.18	Distribution of genotype and allele frequencies of <i>TYR</i> rs1042602 and rs1126809 polymorphisms in vitiligo patients and controls.	82
Table 2.19	Distributions of genotype and allele frequencies of <i>TYR</i> rs1042602 and rs1126809 polymorphisms in different subsets of vitiligo patients and controls.	83
Table 2.20	Distribution of haplotype frequencies for <i>TYR</i> rs1042602 and rs1126809 polymorphisms in vitiligo patients and controls.	84
<b>CHAPTER III</b>		
Table 3.1	Demographic characteristics of vitiligo patients and controls recruited for homocysteine and vitamin B <sub>12</sub> estimation.	109
<b>CHAPTER IV</b>		
Table 4.1	Details of primers used for gene expression analysis.	128